Abstract
Liver fibrosis is reversible by immune treatments in the early stages of cirrhosis development, but not in later stages. At present, the value of the markers for indicating an increased risk of cir...
Highlights
Hepatitis B virus (HBV) infection is a public health challenge
The long-term consequences of HBV infection include the evolution of liver fibrosis (LF) and liver cirrhosis (LC)
The mean difference (MD) and their 95% confidence interval (CI) for serum fibrosis markers are shown in Figures 2 and 3
Summary
About 360 million people are chronically infected with HBV worldwide, including up to 30 million living in China (Jury, 2003; Liang, Chen, & Wang et al, 2005). The long-term consequences of HBV infection include the evolution of liver fibrosis (LF) and liver cirrhosis (LC). The 1-year cumulative incidence of LC in chronic HBV infection is estimated to be 2.1–6% (Chu & Liaw, 2006). Five-year survival with compensated LC is 80–86%, but it is only 14–30% with decompensated LC. The 1-year cumulative incidence of decompensation has been estimated as 10% (de Jongh et al, 1992; Fattovich et al, 2002; Schuppan & Afdhal, 2008). The previous research has revealed that fibrosis is reversible in the early stages of cirrhosis development, but not in later stages (Friedman & Bansal, 2006)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
